View Older Stories View More Recent Stories
-
No Major N-T Impact Expected on Solars Following WTO Statement on U.S. Antidumping Duties - Roth (SCTY) (JASO) (TSL) (YGE)
-
Roth Affirms Verastem (VSTM) at 'Buy'; Encouraged by VS-6063's Potential in Mesothelioma, Ovarian Cancer
-
Tonix Pharmaceuticals (TNXP) Enters 657K Direct Placement at $11.90/Share
-
Roth Capital Downgrades Golden Minerals Company (AUMN) to Neutral
-
Streetinsider.com's Hot Lunchtime Reads 07/10: (CYNK) (MSFT) (SRPT) (CYTK)
-
Roth Capital Keeps Cytokinetics (CYTK) at 'Buy' Following Recent BENEFIT-ALS Update
-
Roth Capital Affirms Regeneron (REGN) at 'Buy' Following Positive Dupilumab Phase 2b Update
-
RGS Energy (RGSE) Closes 2.92M Equity Offering at $2.40/Share
-
RGS Energy Completes $7.0 Million Private Equity Offering
-
PlacementTracker Publishes First Half 2014 PIPE Market League Tables
-
Streetinsider.com's Hot Lunchtime Reads 07/08: (PETM) (AAPL) (CNCE) (MSFT)
-
Roth Capital Keeps Concert Pharma (CNCE) at 'Buy'; SPA Filing is Sign of Confidence in CTP-499
-
Roth Capital Starts PTC Therapeutics (PTCT) at Buy
-
Roth Capital 'Encouraged' by Notice of Intent in Cytori's (CYTX) Contract with BARDA
-
Roth Capital Remains Positive on Spectrum Pharma (SPPI) as Beleodaq Wins Accelerated Approval
-
RGS Energy (RGSE) Prices $7M Equity Raise
-
RGS Energy Prices Equity Offering
-
Roth Reinstates BioLineRx (BLRX) at 'Buy'; Strong Pipeline Reinforces Upside Potential
-
Roth Capital Resumes BioLineRx (BLRX) at Buy
-
Medigus Announces Signing of $11.1 Million Private Placement by Leading Israeli and U.S. Institutions
-
Roth Capital Remains Positive on Stemline (STML); Management Updates on SL-401, SL-701
-
IGI Labs (IG) Prices 4.65M Common Offering at $5 Apiece
-
Roth Capital Starts Dot Hill (HILL) at Buy
-
IGI Laboratories (IG) Annouces Stock Offering
-
Slow Ramp Leaves R-22 Pricing Flat; Roth Keeps Hudson Tech (HDSN) at 'Buy'
-
Roth Capital Keeps LIgand Pharma (LGND) at Buy; Glaxo Initiates Promacta Phase III
-
Wunderlich Expands into Consumer and Business Services Investment Banking
-
Roth Capital Starts Concur Technologies (CNQR) at Buy
-
Roth 'Encouraged' by TG Therapeutics (TGTX), Ligand (LGND) Deal; Issues Commentary
-
Roth Affirms Hydrogenics (HYGS) at Buy; JV with Kolon Water is Step in Right Direction
-
Streetinsider.com's Hot Lunchtime Reads 06/23: (MSFT) (LGND) (RSH) (YELP)
-
Roth Capital Comments on New SERM Lasofoxifene Phase 1 Data
-
Unusual 11 Mid-Day Movers 06/20: (KMX) (FLML) (CARA) Higher; (MACK) (PVCT) (CLRX) Lower
-
SolarCity (SCTY) Continues Higher Following Silevo Deal, Management Commentary
-
Roth Capital Starts Prosensa (RNA) at Neutral
-
Roth Capital Starts Superior Drilling Products (SDPI) at Buy
-
Roth Boosts Target on SolarCity (SCTY) to $80; Silevo Acquisition 'Makes Sense'
-
Yingli Green Energy (YGE) Could See H214 Ramp; Roth Capital Keeps at 'Neutral'
-
Roth 'Impressed' at Early Completion of Enrollment in Galena's (GALE) GALE-301 Phase 2a; Keeps at 'Buy'
-
UPDATE: Short-Seller Article on Ligand (LGND) is Silly, Underlying Strength Remains - Roth Capital
-
LGD-6972 Could Drive Partnership; Roth Keeps Ligand Pharma (LGND) at 'Buy'
-
New Promacta Data Should Support Approval for cITP; Roth has Ligand (LGND) at 'Buy'
-
Roth 'Encouraged' by TG Therapeutics' (TGTX) TG-1101 Phase 2 Prelim Results; Boosts PT to $20
-
Notable Analyst Rating Changes 06/13: (INTC) (GEF) (NMBL) Upgraded; (MRVL) (LULU) (MRO) Downgraded
-
Pre-Open Stock Movers 6/13: (OPEN) (EXPR) (ICLD) Higher; (FNSR) (OCLS) (ETRM) Lower (more...)
-
Roth Capital Starts Conatus Pharmaceuticals (CNAT) at Buy
-
Roth Capital Upgrades Intel (INTC) to Buy
-
Roth Capital Starts Fusion-io (FIO) at Buy
-
Worst of Capstone Turbine (CPST) Probably Priced in; Roth Affirms 'Buy' Rating
-
Roth Comments on Regeneron (REGN), Sanofi Presentation of Sarilumab Phase 3 Data; Affirms at 'Buy'

